AOD 9604 1200mcg/ml 5mL

AOD-9604 1200 mcg/mL 5 mL refers to a research peptide formulation containing AOD-9604, a synthetic fragment of the human growth hormone (HGH) molecule (residues 176–191) that was investigated for effects on fat metabolism. AOD-9604 is designed to mimic the lipolytic (fat-burning) domain of HGH without the broader hormonal effects such as increases in IGF-1. Preclinical studies in animals showed that AOD-9604 could increase lipolysis and reduce weight gain, with research in obese rodent models demonstrating significant effects on adipose tissue metabolism. In mice, both human growth hormone and AOD-9604 reduced body weight and fat through mechanisms involving adrenergic pathways. Human clinical trials have evaluated safety and tolerability in nearly 900 adults across multiple Phase I and Phase II studies. AOD-9604 generally showed a favorable safety profile indistinguishable from placebo and did not produce the adverse effects associated with full-length HGH. In a 12-week randomized trial, subjects receiving AOD-9604 lost more weight than placebo, but a larger 24-week Phase IIb trial did not demonstrate statistically significant weight loss, and development as an obesity drug was discontinued. AOD-9604 remains an experimental peptide and is not FDA-approved for medical use; formulations like 1200 mcg/mL 5 mL are typically used in research or compounding settings under professional supervision. Links for more information: Overview of AOD-9604: https://en.wikipedia.org/wiki/AOD9604 Clinical trial data summary: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/ Human safety and tolerability: https://www.jofem.org/index.php/jofem/article/view/157/194